Rezolute, Inc. Class Action Lawsuit - RZLT

The filed complaint alleges that Rezolute, Inc. made materially false and/or misleading statements and/or failed to disclose that: On December 11, 2025, before the market opened, Rezolute announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism. The company reported that the study did not meet its primary endpoint, as it “was not statistically significant to the placebo group, which experienced a 40% improvement.”. Further, the study did not meet its key secondary endpoint which was also “not statistically significant to the placebo.” Management expressed disappointment noting “we are conducting a thorough evaluation to gain a better understanding of the study outcomes.” Following this news, RZLT’s stock price fell over 89% to open at $1.21 per share.

In order to be eligible to join the RZLT class action lawsuit, you must have incurred a loss on shares of Rezolute, Inc. purchased during the class period listed above.